证券记录 · 已归档季度
COGT
Cogent Biosciences, Inc. · Healthcare · Biotechnology
12被追踪持有人
+2Δ持有人
19.61M持有股份
$211.75M报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +20.0% ·
股份流向 +3.8% ·
净新建仓位 +16.7%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 104 | +4 | 108.47M | $4.20B | +7 | −3 |
| Q1 2026 | 103 | +9 | 108.14M | $4.02B | +15 | −6 |
| Q4 2025 | 92 | +1 | 96.22M | $3.42B | +1 | — |
| Q3 2025 | 20 | +4 | 59.75M | $857.99M | +4 | — |
| Q2 2025 | 13 | -2 | 45.58M | $327.23M | — | −2 |
| Q1 2025 | 12 | -1 | 13.98M | $83.77M | — | −1 |
| Q4 2024 | 13 | 0 | 17.19M | $134.06M | +1 | −1 |
| Q3 2024 | 12 | +2 | 19.61M | $211.75M | +2 | — |
| Q2 2024 | 10 | — | 18.90M | $159.29M | — | — |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 10.47M | 0.0% | $113.08M | 0.4% | Held | 2 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 4.07M | -4.3% | $43.91M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 2.28M | +15.2% | $24.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 2.28M | +15.2% | $24.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 1.61M | +31.0% | $17.43M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 457.23K | +53.1% | $4.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 457.23K | +53.1% | $4.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 342.32K | +8.0% | $3.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 342.32K | +8.0% | $3.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 342.32K | +8.0% | $3.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 342.32K | +8.0% | $3.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 129.41K | -13.2% | $1.40M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 106.62K | -28.6% | $1.15M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 73.91K | 新增 | $798,174 | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 44.16K | +8.7% | $477,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 11.71K | 新增 | $126,489 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 11.71K | 新增 | $126,489 | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 11.71K | 新增 | $126,489 | 0.0% | New | 1 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 9.65K | +6.7% | $104,188 | 0.0% | ▲ Add | 2 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $798,174 | 0.0% |
| AQR Capital Management | $126,489 | 0.0% |
| AQR Capital Management | $126,489 | 0.0% |
| AQR Capital Management | $126,489 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 304 持有人, 186.07M 股份, $6.90B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据